Pair page
CJC-1295 with Retatrutide
Mechanism-tag overlap and published literature for CJC-1295 and Retatrutide, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
ghrhgrowth-hormone-releasing-hormone-analog
incretin-peptidetriple-receptor-agonist
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying CJC-1295 and Retatrutide have published these mechanism-level observations. Not a co-administration recommendation.
Growth hormone secretagogue stack added by some users to support muscle retention during rapid weight loss. Avoid in anyone with a history of cancer or active proliferative disease.
Quick facts
CJC-1295
Retatrutide
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2006 | CJC-1295 | aidsmap. Lipodystrophy study halted after patient death. July 2006. (Reports the ConjuChem Phase 2 CJC-1295 trial halt.) | human trial, Phase 2 |
| 2010 | CJC-1295 | Alexopoulou O, Abs R, Maiter D. Treatment of adult growth hormone deficiency: who, why and how? A review. Acta Clin Belg. 2010;65(1):13-22. PMID: 20373593. PMID 20373593 | human study |
| 2009 | CJC-1295 | Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. PMID: 19540144. PMID 19540144 | human study |
| 2006 | CJC-1295 | Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805… PMID 16352683 | human study |
| 2006 | CJC-1295 | Abla AA, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E… PMID 16835399 | preclinical, in vivo |
| 2005 | CJC-1295 | Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology.… PMID 15817669 | preclinical, in vivo |
| 2005 | CJC-1295 | Alba M, Fintini D, Bowers CY, Parlow AF, Salvatori R. Effects of long-term treatment with growth hormone-releasing peptide-2 in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2005;289(5):E762-E767. | preclinical, in vivo |
| 2020 | CJC-1295 | Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37. | mechanism / discovery |
| 1995 | CJC-1295 | Izdebski J, Pinski J, Horvath JE, Halmos G, Groot K, Schally AV. Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA. 1995;92(10):4872-4876. PMID: 7761412. (Parent work on tetrasubstituted GHRH analogs.) PMID 7761412 | mechanism / discovery |
| 2023 | CJC-1295 | Alwatban MZ, Al-Lohedan HA. A review of CJC-1295 as a GHRH analog: Pharmacology and clinical relevance. Drug Des Devel Ther. 2023 (review series). | review |
| 2026 | CJC-1295 | World Anti-Doping Agency. The 2026 Prohibited List. Section S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org. | regulatory / registry |
| 2025 | CJC-1295 | U.S. Food and Drug Administration. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025. | regulatory / registry |
| 2025 | Retatrutide | Rosenstock J, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025. PMID: 40609566. PMID 40609566 | human trial, Phase 2 |
| 2024 | Retatrutide | Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. PMID: 38858523. PMID 38858523 | human trial, Phase 2 |
| 2023 | Retatrutide | Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315. DOI: 10.1056/NEJMoa2301972. PMID 37366315 | human trial, Phase 2 |
| 2023 | Retatrutide | Rosenstock J, Frías JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544.… PMID 37385280 | human trial, Phase 2 |
| 2025 | Retatrutide | Eli Lilly and Company. Topline TRIUMPH-4 readout — retatrutide in adults with obesity and knee osteoarthritis. Press release, October 2025. | human trial |
| 2023 | Retatrutide | Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131. (Comparator reference.) PMID 37952131 | human trial |
| 2022 | Retatrutide | Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024. (Comparator reference.) PMID 35658024 | human trial |
| 2021 | Retatrutide | Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185. (Comparator reference.) PMID 33567185 | human trial |
| — | Retatrutide | Kjeldsen SAS, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. PMID: 41090431. PMID 41090431 | human trial |
| — | Retatrutide | ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Adult Participants Who Have Obesity or Are Overweight With Weight-Related Medical Problems (TRIUMPH-1). NCT05929066. | human trial |
| — | Retatrutide | ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Adult Participants With Obesity and Type 2 Diabetes (TRIUMPH-2). NCT05929079. | human trial |
| — | Retatrutide | ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight With Osteoarthritis of the Knee (TRIUMPH-4). NCT05931367. | human trial |
Related pair pages
More research context
Frequently asked
Have CJC-1295 and Retatrutide been studied together?
Researchers have published mechanistic-level co-administration discussion of CJC-1295 and Retatrutide. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do CJC-1295 and Retatrutide share?
CJC-1295 and Retatrutide do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of CJC-1295 and Retatrutide?
CJC-1295: Not approved. Retatrutide: Investigational (Phase 3). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on CJC-1295 and Retatrutide?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the CJC-1295 profile and the Retatrutide profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026